{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-003044","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.582415+00:00","generated_at":"2026-05-21T23:01:48.077190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harvard Bioscience Q1 net loss $50.3M includes $48M goodwill impairment; guides Q2 revenue $18-20M","bullets":["Revenue $21.8M vs $24.5M YoY (-11%); net loss $(50.3)M vs $(4.7)M, including $48.0M goodwill impairment.","Gross margin 56.0% vs 60.3% YoY; Adjusted EBITDA $0.8M vs $1.6M YoY.","Q2 2025 guidance: revenue $18M-$20M, gross margin 55%-57%.","CEO cites NIH funding uncertainty, tariff impact on China sales; cost savings ~$1M/qtr starting Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-003044","json":"https://secwatch.observer/filing/0001171843-25-003044.json","markdown":"https://secwatch.observer/filing/0001171843-25-003044.md","text":"https://secwatch.observer/filing/0001171843-25-003044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325003044/0001171843-25-003044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325003044/f8k_051225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:01:48.077190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}